VSEE HEALTH, INC. (VSEE): Nasdaq/NYSE listing notice — VSee Health receives Nasdaq deficiency for late Q2 10-Q; delisting hearing Sept 9

mpany’s filing of an appeal with the Nasdaq Hearings Panel (the “Panel”). A hearing before the Panel is scheduled to be held on September 9, 2025. The Staff’s determination to deny the Company’s request to continue listing on Nasdaq was based on the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file with the Securities and Exchange Commission (the “SEC”) its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the period ended March 31, 2025. On August 20, 2025, the Company

August 20, 2025, the Company received an additional notice from the Staff that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The Company intends to address all late filings before the Panel at the scheduled hearing. While the Company pursues those processes, trading in the Company’s common stock and public warrants will be suspended on Nasdaq after August 28, 2025, unless the Panel grants an additional extension. As a result of the suspension in tradi